Skip to main content
GeneOne Life Science, Inc. logo

GeneOne Life Science, Inc. — Investor Relations & Filings

Ticker · 011000 ISIN · KR7011000007 KO Professional, scientific and technical activities
Open in API
Filings indexed 490 across all filing types
Latest filing 2025-05-15 Director's Dealing
Country KR South Korea
Listing KO 011000

About GeneOne Life Science, Inc.

https://www.genels.com/en/

GeneOne Life Science, Inc. is a biopharmaceutical research and development company specializing in nucleic acid-based biomedicines. The company's core focus is on developing DNA and mRNA vaccines, particularly for emerging infectious diseases, leveraging its rapid development platforms. In therapeutics, GeneOne utilizes a proprietary DNA plasmid delivery technology to enable the expression of recombinant proteins and plasmid-encoded monoclonal antibodies (Plas-mAbs®). This non-viral vector approach is designed to offer a safer and more cost-effective alternative to traditional gene therapies and cell-line derived monoclonal antibody treatments for conditions such as cancers and autoimmune disorders. The company also develops immunomodulatory small molecule drugs. Through its subsidiary, GeneOne possesses cGMP-grade manufacturing capabilities for DNA plasmids, supporting its internal pipeline and contract manufacturing services.

Recent filings

Filing Released Lang Actions
최대주주등소유주식변동신고서
Director's Dealing Classification · 100% confidence The document is a 'Report of Change in Shareholding by Major Shareholders' (최대주주등소유주식변동신고서) for GeneOne Life Science. It details specific transactions (sales) made by company executives/directors (e.g., Choi Sung-ho). This falls under the category of Director's Dealing (DIRS), which covers personal share transactions by company directors and executives.
2025-05-15 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서), which is a regulatory filing required under the Capital Markets Act in South Korea when an entity or individual acquires a significant stake (typically 5% or more) in a listed company. This document details the acquisition of shares by 'Dongban Growth Investment Association No. 1' in 'GeneOne Life Science'. It is a formal disclosure of major shareholding, not an announcement of a report or a general regulatory filing, fitting the specific definition of a Major Shareholding Notification.
2025-05-14 Korean
유상증자또는주식관련사채등의발행결과(자율공시)
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from GeneOne Life Science regarding the results of a capital increase (paid-in capital increase/third-party allocation). It details the number of shares issued, the amount raised, and the payment date. This falls under the category of share issuance and capital changes.
2025-05-08 Korean
[기재정정]임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities. This type of filing, which details personal share transactions (disposals/acquisitions) by company directors or executives, is classified as 'Director's Dealing' (DIRS) in the provided schema.
2025-05-02 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by major shareholders and special related parties (directors/executives). This specific type of filing, which tracks significant ownership thresholds and changes in control, is classified as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2025-04-30 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities. This type of filing is a standard regulatory requirement for insiders (directors/executives) to disclose changes in their personal shareholdings. According to the provided definitions, reports of personal share transactions by company directors and executives are classified as 'Director's Dealing' (DIRS).
2025-04-30 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.